KSD-101
Phase 1Biologic
KSD-101 is one of 38 biologic programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 1.
1
Indications
3
Total Trials
3
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
282 competitors in Nasopharyngeal Carcinoma
#DrugCompanyPhaseTrials
1Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Tuoyi
SSun Yat-sen University
Phase 3
Erbitux
IImclone
Phase 3
Paraplatin
AAvyxa
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Zovirax
BBp Consulting, Inc
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Albumin-Bound Paclitaxel
Bristol-Myers SquibbPhase 3
Gemcitabine/cisplatin
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nasopharyngeal Carcinoma2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KSD-101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- KKousai Bio Co., Ltd.